Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

NCT05870761 is registered in ClinicalTrials.gov with Casey Cosgrove as lead sponsor.

NCT NCT05870761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05870761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
Lead sponsor
Casey Cosgrove
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 17, 2023
Completion date
July 31, 2026
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent endometrial serous adenocarcinoma